Skip to main content
Chison Medical Technologies Co.,Ltd. logo

Chison Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688358 ISIN · CNE1000076R4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2023-10-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688358

About Chison Medical Technologies Co.,Ltd.

https://www.chison.com/

Chison Medical Technologies Co.,Ltd. specializes in the research, development, and manufacturing of diagnostic ultrasound systems. The company offers a comprehensive portfolio of medical imaging solutions, including trolley-based color Doppler systems, portable ultrasound units, and specialized handheld devices. Its products integrate advanced imaging technologies such as 4D imaging, artificial intelligence-assisted diagnostics, and high-resolution transducers to support clinical applications in cardiology, obstetrics, gynecology, and point-of-care settings. Chison focuses on delivering high-performance diagnostic tools to healthcare providers, supported by a global network of research centers and distribution channels. The company emphasizes continuous innovation in digital signal processing and transducer technology to enhance diagnostic accuracy and clinical workflow efficiency.

Recent filings

Filing Released Lang Actions
祥生医疗第三届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Supervisory Board of Wuxi Xiangsheng Medical Technology Co., Ltd. regarding the resolutions passed at the fourth meeting of the third Supervisory Board. It includes approval of the company's 2023 third quarter report and a decision on the postponement of some fundraising projects. The document states that the detailed 2023 third quarter report is published separately on the Shanghai Stock Exchange website and provides a reference to another announcement about the fundraising project delay. The document itself does not contain the full financial statements or substantive financial data but rather confirms the approval and legality of the report and decisions. The document length is short (1160 characters), and it serves as an official announcement of meeting resolutions and references to other reports. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not as the actual quarterly report or fundraising update.
2023-10-26 Chinese
祥生医疗关于部分募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Wuxi Xiangsheng Medical Technology Co., Ltd. regarding the delay of certain projects funded by proceeds from their initial public offering (IPO). It details the original and adjusted timelines for project completion, reasons for the delay, and confirms that the investment amounts and project scope remain unchanged. The document includes opinions from independent directors, the supervisory board, and the sponsoring institution, all agreeing with the delay. The content focuses on the management and use of raised capital and the company's compliance with regulatory requirements related to fundraising projects. There is no detailed financial data or comprehensive financial statements, nor is it a full annual or interim report. It is not a simple notice of report publication or a certification. The document is best classified as a Capital/Financing Update (CAP) because it provides an update on the use and timing of capital raised through financing activities (IPO proceeds) and changes in project timelines related to that capital.
2023-10-26 Chinese
祥生医疗关于召开2023年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2023 third extraordinary general meeting of shareholders for Wuxi Xiangsheng Medical Technology Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and proxy authorization. There are no financial statements, earnings data, or detailed management discussions. The document is an announcement of a shareholder meeting, not a report or transcript. It does not contain voting results or changes in management. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to prepare for voting at the meeting.
2023-10-26 Chinese
祥生医疗关于公司控股股东上层股权结构变动的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding changes in the equity structure of the company's controlling shareholder. It details internal share transfers among family members within the controlling shareholder entity, clarifies that the controlling shareholder and actual controller remain unchanged, and states that the changes will not affect company operations or trigger a takeover offer. There are no financial statements, audit information, or regulatory certifications present. The document is an announcement of a change in major shareholding structure but does not indicate a change in control or crossing of ownership thresholds that would trigger a Major Shareholding Notification. Instead, it is a notification about internal shareholding changes within the controlling shareholder. This fits best under the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels, even if the controlling shareholder remains the same. The document length is short and focused on shareholding changes, not a full report or financial disclosure.
2023-10-20 Chinese
祥生医疗第三届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Wuxi Xiangsheng Medical Technology Co., Ltd. It details the approval of a restricted stock incentive plan grant to certain recipients. The text includes meeting date, voting results, and references to compliance with company law and internal regulations. There is no financial statement or detailed financial data presented, nor is this a transcript or presentation. It is not an annual or interim report, nor an earnings release. The document is specifically about a board decision regarding stock incentives, which falls under Board/Management Information (MANG). The document length is short (1105 characters), and it is a direct announcement of a board resolution, not a report publication or regulatory filing. Therefore, the classification is MANG with high confidence.
2023-10-16 Chinese
祥生医疗监事会关于公司2022年限制性股票激励计划预留授予激励对象名单的核查意见
Capital/Financing Update Classification · 95% confidence The document is a supervisory board opinion on the reserved grant list of incentive targets under the company's 2022 restricted stock incentive plan. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and approval of the reserved grant date and price. This is a formal announcement related to a stock incentive plan, specifically about the reserved grant of restricted shares. It is not a full financial report, audit, or earnings release, nor is it a general regulatory filing or management change. The content fits best under Capital/Financing Update (CAP) as it relates to stock incentive grants and capital allocation to employees.
2023-10-16 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.